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Abstract
Until very few years ago, the oncology community dogmatically excluded any clinical potential for immunotherapy
in controlling brain metastases. Therefore, despite the significant therapeutic efficacy of monoclonal antibodies to
immune check-point(s) across a wide range of tumor types, patients with brain disease were invariably excluded
from clinical trials with these agents. Recent insights on the immune landscape of the central nervous system, as
well as of the brain tumor microenvironment, are shedding light on the immune-biology of brain metastases.
Interestingly, retrospective analyses, case series, and initial prospective clinical trials have recently investigated
the role of different immune check-point inhibitors in brain metastases, reporting a significant clinical activity
also in this subset of patients. These findings, and their swift translation in the daily practice, are driving fundamental
changes in the clinical management of patients with brain metastases, and raise important neuroradiologic challenges.
Along this line, neuro-oncology undoubtedly represents an additional area of active investigation and of growing
interest to support medical oncologists in the evaluation of clinical responses of brain metastases to ICI treatment,
and in the management of neurologic immune-related adverse events.
Aim of this review is to summarize the most recent findings on brain metastases immunobiology, on the evolving
scenario of clinical efficacy of ICI therapy in patients with brain metastases, as well as on the increasing relevance of
neuroradiology in this therapeutic setting.
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Background
The occurrence of brain metastases in solid tumors is
steadily increasing [1]. About 50% of cancer patients will
experience metastatic spreading to the central nervous
system (CNS) in the course of their disease [2–4], with
the highest incidence been reported in melanoma
(28.2%), lung (26.8%), renal (10.8%), and breast cancer
(7.6%) [5]. The prognosis and survival of patients with
brain metastases remains poor; relevant prognostic fac-
tors include age, primary disease control, presence of ex-
tracranial metastases or leptomeningeal disease, and
performance status, though their clinical value is limited
[6]. The overall 2 and 5 year survival estimates for
patients who develop brain metastases across different
tumor types are 8.1 and 2.4%, respectively, and disease
spreading to the CNS represents the cause of death in
more than half of these subjects [6]. Therapeutic options
for patients with brain metastases are largely palliative
and include surgical resection, whole-brain radiation
therapy (WBRT), stereotactic radiosurgery (SRS), or
their combinations [4], while chemotherapy is uncom-
monly utilized due to its acknowledged limitation to ef-
fectively cross the blood-brain barrier [1]. This latter
notion, and the poorer prognosis of patients with brain
metastases has led them to be generally excluded from
clinical trials with chemotherapeutic agents in the past; a
similar scenario applied also more recently to immuno-
therapy with immune check-point inhibitors (ICI) [7].
However, in the last years, many scientific efforts were
directed to the study of the interactions between im-
mune system and tumor microenvironment (TME) in
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brain metastases allowing to identify CNS as an im-
munologically distinct rather than an immune-isolated
compartment [8]. The inflammatory TME of brain me-
tastases has shown to be active in the majority of pa-
tients with dense infiltration of tumor-infiltrating
lymphocytes (TIL) often expressing immunosuppressive
factors like programmed death-1 (PD-1) ligand (PD-L1)
[9]. These notions and the recent availability of effective
immunotherapeutic agents [10, 11], including anti-
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4),
anti- PD-1, and PD-L1 monoclonal antibodies (mAbs),
have supported their use, also in patients with brain
metastases, as well as in primary CNS tumors [12].
In this manuscript we focus on the upcoming clinical
evidence demonstrating the effectiveness of immuno-
therapy with ICI in brain metastases, and on the daily
practice implications of these finding. Lastly, we high-
light potential future avenues for a more effective immu-
notherapeutic approach for the treatment of brain
metastases.
Brain tumor microenvironment immunobiology
The tumor microenvironment (TME) of metastatic CNS
malignancies, with its highly complex cancer-promoting
features, is considered among the main regulators of the
response and resistance to treatment [13]. Other than
endothelial cells, the brain TME consists of different cell
types including fibroblasts, pericytes, microglia and as-
trocytes, along with a variety of immune cells with sup-
pressive or stimulatory functions [14] physically
protected by the blood-brain barrier (BBB). It was shown
that the BBB in brain metastases is often compromised,
not fully disrupted but rather remodeled into a blood-
tumor barrier due to alterations in the pericyte subpopu-
lation [15] encouraging a robust infiltration of multiple
immune suppressive cell types from the peripheral circu-
lation [8]. The dynamic interactions occurring between
these diverse cell types and cancer cells may contribute
to the metastatic progression and may impair response
to therapy. Cancer cells metastatic to the brain and as-
trocytes can stimulate each other directly [16] or
through the release of different cytokines and inflamma-
tory mediators, contributing to brain colonization [8].
Indeed, interleukin (IL) -8, macrophage migration in-
hibitory factor (MIF), and plasminogen activator
inhibitor-1 (PAI-1) released by metastatic lung cancer
cells were found to be able to activate astrocytes that
produced growth factors [i.e., IL-6, IL-1β, and tumor ne-
crosis factor-α (TNF-α)], thus fostering cancer cell
growth in the brain niche [17]. Moreover, in vitro stud-
ies demonstrated that neurotrophic factors secreted by
reactive astrocytes such as IL-6, transforming growth
factor-β (TGF-β), insulin-like growth factor-1 (IGF-1),
and chemokine ligand 12a (CXCL12a) may contribute to
the development of brain metastasis from breast cancer
[18, 19]. In addition, brain-metastasizing melanoma cells
were found to reprogram astrocytes to express the pro-
inflammatory cytokine IL-23, which stimulated the
secretion of matrix metalloproteinase-2 (MMP-2) en-
hancing the degradation of the extracellular matrix, and
facilitating the extravasation and eventually brain inva-
sion by tumor cells [20].
Besides “resident” astrocytes, type 2 tumor-associated
macrophages [21], myeloid-derived suppressor cells
(MDSC), regulatory T cells (T-reg) [14], and cancer-
associated fibroblasts (CAF) with pro-tumorigenic char-
acteristics were found to be recruited in the brain by
metastatic melanoma, breast and colon cancer [22, 23].
These different cell types were shown to play a negative
role in the anti-tumor immune response by reducing the
expression of key molecules involved in T-cell co-
stimulation (e.g., CD80, CD86, CD40) [8], impairing
antigen presentation [24], and deregulating the homeo-
stasis of the brain microenvironment [8]. In this highly
suppressive TME metastatic landscape, TIL are poorly
represented and functionally impaired in brain metasta-
ses, compared to primary tumors [25]. Along this line,
different studies documented a down-regulated T-cell
activity as the result of tumor-induced T cell exhaustion
in brain metastasis; indeed, PD-1 expression was de-
tected on > 60% of TIL [16], though a correlation with
clinical outcome remains to be investigated.
Besides the analyses of the different cell population in
the brain metastases TME, controversial results have been
reported on the exclusive brain metastases molecular pro-
files. Although several studies demonstrated a genetically
divergence [e.g., higher rates of BRAF mutations, higher
tumor mutational burden (TMB), higher PD-L1 expres-
sion, private gene mutations] between brain metastases
and their primary tumors [26–28], no significant differ-
ences were observed in mutation profiles between a case
series of breast cancer brain metastases and their primary
lesions [29]. These findings suggested that additional stud-
ies are required to fully identify the unique molecular
characteristics/features of brain metastases.
The immunosuppressive role of TME of CNS metasta-
ses highlights the need for new therapeutic approaches
promoting M1 properties of macrophages, the recruit-
ment of tumor infiltrating CD8 + T cell [30], or targeting
suppressive cell types such as T-reg and MDSC. Along
this line, it has been demonstrated that the coadminis-
tration of a Treg-depleting anti-CD25 mAb and IL-21-
engineered cell vaccine led to the cure of most mice
bearing TS/A micrometastases [31].. Moreover, strat-
egies aiming at converting the immune-suppressive mi-
lieus into inflamed environments [31, 32] through the
use of antibodies against suppressive cytokines such as
TGF-β, or IL-10 may play a relevant role [33]. In this
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context, the overexpression of TGF-β2 by melanoma
cells was associated with site-specific brain metastasis;
and, accordingly, the use of anti-TGF-β2 therapies in a
syngeneic murine melanoma model significantly reduced
metastasis to the brain [34].
Upcoming findings suggest that epigenetic modeling
may also contribute to the immune-suppressive tumor
and TME profile of brain metastases. Initial evidence
supporting this hypothesis derived from the exploration
of the methylomes of lung, breast, and cutaneous mel-
anoma brain metastases, and from their relative
primary tumors. These studies allowed building epigen-
etic classifiers able to determine the origin of brain me-
tastases, the histotype of primary CNS tumors, and also
the therapeutic subtype for breast cancer patients [34].
Consistent with the notion that epigenetic modeling
plays a relevant role in shaping brain metastases, genes
involved in cell development and differentiation, regu-
lation of gene expression, cell migration, and tumor
suppression were found to be unmethylated in the ma-
jority of breast cancer patients without brain metastases
as compared to those with CNS involvement [35].
These findings, and the well-known immunomodula-
tory potential of DNA hypomethylating agents on genes
involved antigen processing and presentation [36], and
on immunosuppressive cellular and soluble compo-
nents of the TME of brain metastases (e.g., MDSC, T-
reg, chemokines) [37, 38], strongly support the use of
epigenetic drugs combined with ICI to develop new
strategies for the personalized therapeutic management
of patients with brain metastases.
ICI therapy of brain metastases
Melanoma
The initial clinical evidence of ICI activity in melanoma
brain metastases was generated in two prospective phase
II studies. The first trial investigated the efficacy of ipili-
mumab in patients with asymptomatic (n = 51, cohort A)
or symptomatic (n = 21, cohort B) brain metastases [39].
CNS disease control rate (DCR) at 12 weeks was 24 and
10%, and the intracranial overall response rate (ORR)
was 16 and 5%, in cohorts A and B, respectively; median
overall survival (OS) was 7 months (range 0.4–31+) for
cohort A, and 4months (0.5–25+) for cohort B, while
survival rates at 24 months were 26, and 10%, respect-
ively. Though initial, these results suggested a better effi-
cacy of treatment in patients with asymptomatic brain
metastases and who did not receive steroids. In the
phase II Italian Network for Tumor Biotherapy (NIBIT)-
M1 study, 86 patients with metastatic melanoma
received ipilimumab at 10 mg/kg combined with fote-
mustine: among the 20 patients who also had asymp-
tomatic brain metastases at study enrolment the ir-DCR
was 50%, and it was 46.5% in the whole population [40].
Also, the 3 year OS was 27.8% in patients with brain me-
tastases and 28.5% in the whole population, suggesting a
durable clinical benefit of treatment also in patients with
asymptomatic brain metastases [41]. A more recent
follow-up of this study has shown that 5 complete re-
gressions of brain disease were obtained, with a duration
of brain complete response (CR) of 16, 28, 39, 80+, 94+
months; of note, the 2 patients still alive, in the absence
of subsequent treatment, had achieved a CR both intra-
and extra-cranial (A.M. Di Giacomo, et al. unpublished).
Based on this intriguing clinical evidence and on avail-
able results showing an additive therapeutic efficacy of
ipilimumab combined with nivolumab in melanoma
[42], the multicentre, phase III, randomized, open-label
NIBIT-M2 study, sponsored by the NIBIT Foundation,
was activated [43]. This three-arm study was designed to
assess the OS of previously untreated metastatic melan-
oma patients with asymptomatic brain metastases who
received fotemustine, its combination with ipilimumab,
or the combination of ipilimumab and nivolumab. Re-
sults from a pre-planned interim analysis of the study
will be soon available.
Providing additional support to the notion that pa-
tients with brain metastases can benefit from ICI treat-
ment, the activity of anti-PD-1 monotherapy was
recently reported in a retrospective analysis of 66 melan-
oma patients with CNS disease treated with nivolumab
or pembrolizumab [44]. An intracranial ORR and DCR
of 21 and 56%, respectively, with a median OS of 9.9
months was observed [44]. Moreover, in a prospective
phase II study, pembrolizumab induced in 23 melanoma
patients an intracranial ORR of 26%, with 2 partial re-
sponses (PR) and 4 CR. With a median follow-up of 24
months the median progression free survival (PFS) and
OS were 2 and 17months, respectively, and 11 patients
(48%) were still alive at 2 years [45].
Two additional studies have recently investigated the
dual blockade of CTLA-4 and PD-1 molecules in melan-
oma patients metastatic to the brain. The phase II,
single-arm, CheckMate 204 study enrolled patients with
asymptomatic brain metastases measuring 0.5–3.0 cm,
that were treated with a combination of ipilimumab and
nivolumab for 4 cycles, followed by nivolumab mainten-
ance until progression or unacceptable toxicity [46].
Among the 94 enrolled patients the intracranial and ex-
tracranial ORR were 55 and 50%, respectively, with a
global ORR of 51%, and with 90% ongoing objective re-
sponses at a relatively short median duration of follow-
up of 14 months [46]. A recent update of the study with
a median follow-up of 20.6 months, reported an intracra-
nial and extracranial ORR of 54 and 49%, respectively,
with a global ORR of 51%, among the 101 evaluable pa-
tients with asymptomatic brain metastases; the 18
months survival rate was 75% [47]. Noteworthy, results
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from a cohort of 18 patients with symptomatic brain
metastases demonstrated an intracranial, extracranial,
and global ORR of 22%, with a 6 months survival rate of
66% at a median follow-up of 5.2 months [47]. Consist-
ent with these results are those from the Australian
Brain Collaboration (ABC) study, a phase II, prospective
trial enrolling 3 cohorts of patients with asymptomatic
or symptomatic brain metastases [48]. Subjects with no
prior local brain treatment were randomly assigned to
receive nivolumab combined with ipilimumab (Cohort
A) or nivolumab alone (Cohort B), whereas symptomatic
patients who had failed local brain therapy and/or had
leptomeningeal spreading disease received nivolumab
alone (Cohort C). The intracranial ORR was 46, 20,
and 6% in Cohorts A, B and C, respectively. Among
patients enrolled in Cohort A, those with treatment-
naïve brain disease achieved a 56% ORR while it was
16% in BRAF mutant patients pre-treated with BRAF
and MEK inhibitors [48]. Corroborating the safety re-
sults from CheckMate 204 study, treatment-related
grade 3/4 adverse events occurred in 19 patients
(54%) in Cohort A, in one patient (4%) in Cohort B,
and in two patients (13%) in Cohort C, with no unex-
pected toxicities; these findings supported the safety
and tolerability of nivolumab alone or in combination
with ipilimumab in melanoma patients with brain me-
tastases [48].
Overall, data from these prospective clinical trials
demonstrate safety and efficacy of anti-CTLA-4 plus
anti-PD-1 therapy, coupled with important ORR, simi-
lar to those reported in extracranial sites. The find-
ings are highly encouraging and strongly support the
role of ICI therapy also in patients with brain metas-
tases (Table 1). Importantly, additional therapeutic
combinations in melanoma patients with brain metas-
tases are being explored, as summarized in Table 2.
Lung Cancer
As it had previously occurred for melanoma, patients
with non-small cell lung cancer (NSCLC) and active
brain metastases were excluded from pivotal clinical tri-
als with ICI, and only a few retrospective analyses have
presently investigated the efficacy and safety of ICI ther-
apy in this patient population. In a prospective phase II
trial pembrolizumab induced an intracranial ORR in 10
out of 34 (29.4%) PD-L1+ patients, with no objective re-
sponse in the 5 PD-L1− patients treated. The median OS
among all patients was 8.9 months, and 31% of patients
were alive at 2 years [49]. A pooled analysis from the
three CheckMate studies 063 (phase II), 017 (phase III),
and 057 (phase III), explored the role of nivolumab in
NSCLC patients with previously treated or untreated
asymptomatic brain metastases [50]. Among evaluable
patients with pre-treated brain metastases at the time of
overall disease progression (PD) or last tumor assess-
ment, 33% had no evidence of CNS progression while
52% had progressive brain disease; median OS was lon-
ger in the nivolumab group (8.4 months) as compared to
the chemotherapy (docetaxel) group (6.2 months). Sup-
porting the efficacy of ICI in NSCLC patients with brain
metastases, the Italian expanded access program (EAP)
with nivolumab enrolled 409 patients with asymptomatic
or pretreated brain metastases who achieved an ORR of
17% and a DCR of 40% [51].
In addition, an exploratory subgroup analysis of the
OAK study [52], assessing the safety and efficacy of the
anti-PD-L1 atezolizumab in patients with or without a
history of asymptomatic, treated brain metastases, has
shown an acceptable safety profile with a trend toward
an OS benefit of atezolizumab versus docetaxel (16 ver-
sus 11.9 months). Interestingly, atezolizumab led to a
prolonged time to radiologic identification of new symp-
tomatic brain metastases compared with docetaxel [53].
Table 1 Efficacy of immune checkpoint inhibitors in melanoma brain metastases
Author Phase Agent No. Patients Intracranial ORR (%)
Margolin (2012) II Ipi
Cohort A 51 16
Cohort B 21 5
Di Giacomo (2012) II Ipi + Fotemustine 20 50
Parakh (2017) Real-world (retrospective) Nivo or Pembro 66 21
Kluger (2019) II Pembro 23 26
Long (2017) II
Cohort A Ipi + Nivo 26 46
Cohort B Nivo 25 20
Cohort C Nivo 16 6
Tawbi (2018) II Ipi + Nivo 94 55
Ipi Ipilimumab, Nivo Nivolumab, Pembro Pembrolizumab, ORR Object Response Rate
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Aiming to expand these initial intriguing observations,
supporting the role of immunotherapy also in lung can-
cer patients with brain disease, several ongoing prospect-
ive clinical trials are investigating the efficacy and safety
of ICI in NSCLC and small cell lung cancer (SCLC) pa-
tients with brain metastases (Table 2). Moreover, initial
studies aim to explore the role of new prognostic and
predictive biomarkers also in NSCLC with brain metas-
tases [54, 55].
Renal cell carcinoma
The 5 year cumulative incidence of brain metastases in
renal cell carcinoma (RCC) ranges from 7 to 13% [56],
and limited data are available on the efficacy of current
systemic treatment of brain disease in RCC patients. To
date the vast majority of prospective trials in RCC
allowed the inclusion of patients with stable brain dis-
ease, and none of the pivotal trials with ICI reported the
efficacy of the immunotherapy in patients with active
brain metastases. Initial signs of clinical activity for ICI
therapy in brain metastases from RCC derived from case
reports and small observational series. Among the latter,
the Italian EAP with nivolumab enrolled 389 patients be-
yond first-line therapy, of whom 32 (8%) had asymptom-
atic brain metastases that did not require radiotherapy
or high dose steroids (i.e., > 10 mg of prednisone). The 6
and 12 months survival rates of these patients were 87
and 66.8%, and they were 80.0 and 63.1% in the overall
population; the DCR was 53.1 and 53.0% in patients with
or without brain metastases, respectively. Treatment re-
lated adverse events (AE) were similar between patients
with CNS metastases and the overall population (31% vs
32%); however, grade 3–4 toxicities were more frequent
(12% vs 7%) in patients with brain disease [57]. The
French phase II study GETUG-AFU 26 NIVOREN also
evaluated safety and efficacy of nivolumab in metastatic
Table 2 Summary of ongoing clinical trials with ICI in solid tumor with brain metastasesa
Clinical trial
identifier
Trial Name Phase Status
NCT03175432 Study of Bevacizumab in Combination With Atezolizumab in Patients With Untreated Melanoma Brain
Metastases (BEAT-MBM)
II Recruiting
NCT02460068 A Study of Fotemustine (FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain
Metastasis (NIBIT-M2)
III Recruiting
NCT03340129 Anti-PD 1 Brain Collaboration + Radiotherapy (ABC-X Study) (ABC-X) II Not yet
recruiting
NCT03728465 Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma II Recruiting
NCT02681549 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small
Cell Lung Cancer
II Recruiting
NCT02858869 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases I Recruiting
NCT03563729 Melanoma Metastasized to the Brain and Steroids (MEMBRAINS) II Recruiting
NCT03873818 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain II Recruiting
NCT02130466 A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and
Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) (patients with inactive brain
metastases eligible)
I/II Recruiting
NCT02696993 Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases
From Non-small Cell Lung Cancer
I/II Recruiting
NCT02978404 Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases II Recruiting
NCT02886585 Pembrolizumab In Central Nervous System Metastases II Recruiting
NCT03867175 Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer III Not yet
Recruiting
NCT03719768 Avelumab With Radiotherapy in Patients With Leptomeningeal Disease I Recruiting
NCT03325166 Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell
Lung Cancer and Brain Metastases
II Recruiting
NCT02648477 Pembrolizumab and doxorubicin hydrochloride or anti-estrogen therapy in treating patients with triple-
negative or hormone receptor-positive metastatic breast cancer
II Recruiting
NCT03483012 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis II Recruiting
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (SRS) Of Selected Brain Metastases In Breast Cancer Patients I/II Recruiting
NCT03526900 Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With
Asymptomatic Brain Metastasis (ATEZO-BRAIN)
II Recruiting
a as of Sep 4, 2019. Source: clinicaltrials.gov
ABC Australian Brain Collaboration, SRS/SBRT stereotactic radiosurgery
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RCC after progression on vascular endothelial growth
factor receptor (VEGFR)-directed therapies [58].
Seventy-three patients with asymptomatic brain metasta-
ses were treated: Cohort A included 39 patients who had
not received any prior brain therapy (i.e., surgery, radi-
ation, steroids) while Cohort B included 34 patients who
had received prior local treatment (primarily SRS). The
primary endpoint was the intracranial ORR in Cohort A
according to modified Response Evaluation Criteria in
Solid Tumors (RECIST) criteria, allowing target lesions
≥5mm. Intracranial ORR was 12% in Cohort A but no
objective responses were observed in patients with mul-
tiple brain lesions or larger than 1 cm. At a median fol-
low up of 23.6 months median duration of treatment
was 4.9 months in Cohort A, with 13% of patients still
on therapy at the time of analysis. Interestingly, the
intracranial median PFS was 2.7 months and the 12
months OS rate was 67% [58]. Additional data derived
from the phase 3/4 study CheckMate 920 combining
treatment with ipilimumab and nivolumab. The study
enrolled 28 RCC patients with non-active brain metasta-
ses of whom 21 had non-target lesions at baseline (le-
sions < 10 mm or previously irradiated): the ORR was
29% with no CR and 8 PR; median PFS was 9.0 months
and the 6months survival rate was 89%. The incidence of
immune-related (ir) AEs was generally consistent with the
global safety profile of the combination [59]. These data,
despite the limited case series, suggest for the efficacy and
safety of ICI also in brain metastases from RCC, though
further investigation in prospective clinical trials is needed
to draw more solid conclusions on its efficacy in this
subset of patients. In fact, recent evidence supports the
notion that responsiveness to immunotherapy in RCC
with brain disease seems to be multifactorial and hetero-
geneous, therefore several factors (e.g., TME components,
genetic intratumoral heterogeneity, compartment- or
location-specific alterations of signaling pathways) need to
be further explored to improve efficacy of ICI treatment
in RCC with brain metastases [60]..
Table 2 reports the ongoing clinical trial with ICI in
patients with RCC metastatic to the brain.
Neuroradiology and immunotherapy response evaluation
Optimal therapeutic management of cancer patients
benefits from reliable diagnostic, prognostic and predict-
ive imaging markers, aiming to identify successful
treatment prior to changes in tumor size. In the thera-
peutic management of brain metastases, neuroradiology
[61, 62] provides i) number, location, and size of brain
metastases at diagnosis, ii) the differential diagnosis ver-
sus a wide range of pathologic conditions including pri-
mary tumors, vascular malformations, ischemia,
hemorrhage, and seizure [63], iii) evaluation of treatment
response, and iv) diagnosis of treatment-related AEs or
complications. Magnetic resonance imaging (MRI) re-
placed computed tomography (CT) as the imaging mo-
dality of choice for brain metastases in the 1980s.
Magnetic field, gradients, advanced sequences, hardware,
and software are greatly expanding, as well as image
post-processing, allowing quantitative data extraction
and analysis capabilities. Positron emission tomography
(PET) scanning also has advanced with the more wide-
spread adoption of amino acid tracers replacing trad-
itional [18F]-fluorodeoxyglucose, with improvements in
signal-to-noise ratio and diagnostic sensitivity and
specificity.
Diagnosis and differential diagnosis
Head CT is generally reserved to staging and restaging
of asymptomatic patients, as well as, in the emergency
setting, to rule out hemorrhage, ischemia, and hydro-
cephalus. Instead, MRI is undoubtedly the gold standard
technique that should be utilized in all patients with ma-
lignant disease and with a clinical history suggestive for
brain metastases [64]. According to the European Soci-
ety for Medical Oncology guidelines, head MRI screen-
ing for brain metastases in patients with unresectable
stage III or IV lung cancer is recommended, even
though they are neurologically asymptomatic; addition-
ally, head MRI should be utilized prior to curative sur-
gery, regardless of the preoperative stage [65, 66].
Conversely, brain imaging should not be carried out rou-
tinely in asymptomatic metastatic breast cancer patients
[67], and for melanoma patients there is currently no
consensus on its frequency during the clinical follow-up
[68]. The MRI protocol study needs unenhanced T1-
weighted, fluid attenuated inversion recovery, T2-
weighted, T2*-weighted or susceptibility-weighted
images which clearly differentiates abnormal from nor-
mal signals of the nervous tissue. Gadolinium-enhanced
T1-weighted magnetic resonance (MR) images are the
mainstay of the neuroradiological evaluation of brain
metastases since they are easy to perform, and accurately
depict the margins of most intra-axial metastases, as well
as leptomeningeal, dural-based, and bone metastases.
Furthermore, non-morphological or so-called “func-
tional” or “physiological” or “advanced” MR techniques
may be useful to further differentiate brain metastases
from other neoplastic and non-neoplastic lesions. Most
common advanced MR techniques are diffusion
weighted imaging with apparent diffusion coefficient
measure, perfusion- and permeability-weighted imaging,
and MR spectroscopy; however, none of these
techniques alone has been proven to be highly specific
[62, 69–71]. Thus, a thoughtful synthesis using a com-
bination of these techniques can usually allow the neu-
roradiologist to correctly discriminate tissues.
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Response evaluation
Available therapeutic options including surgery, radiation,
chemotherapy, and most recently immunotherapy, may
significantly affect the imaging features of both brain me-
tastases and brain parenchima, resulting in a quite com-
plex neuroradiological interpretation of post-treatment
findings. Notably, the broader application of cancer im-
munotherapy to patients with brain disease, makes the
complexity of neuroradiologic tumor response evaluation
increasingly challenging for the neuroradiologist. Clinical
responses occurring after initial disease progression or
even after the appearance of new lesions, treatment-
induced inflammation, long-term benefit and tumor re-
gression are in fact frequent features in the course of
immunotherapy.
Thus, aiming to standardize the radiological evalu-
ation of brain metastases, the Response Assessment in
Neuro-Oncology (RANO) Brain Metastases (RANO-
BM) group proposed novel evaluation criteria focused
on the objective measurement of tumor size at
gadolinium-enhanced T1-weighted MR images, cortico-
steroid use, and clinical deterioration [72]. The RANO-
BM were subsequently incorporated into the immuno-
therapy RANO (iRANO) criteria [73], providing recom-
mendations for the interpretation of neuroradiological
changes in the course of immunotherapy. Specifically,
in the absence of worsening neurologic signs, the
iRANO recommend a 3 months confirmation of initial
PD, within 6 months from the beginning of treatment.
If follow-up neuroradiology confirms disease progres-
sion, the date of actual progression should be backdated
to the date of first neuroradiogical assessment of PD.
Also, the appearance of new lesions 6 months or less
from the beginning of immunotherapy does not define
PD [73].
Of note, the iRANO criteria are limited to intra-
axial brain metastases, as leptomeningeal and skull
bone metastases are often more difficult to be object-
ively measured and followed, and thus still rely on a
qualitative evaluation. Therefore, the RANO group
had initially proposed a Leptomeningeal Assessment
in Neuro-Oncology (LANO) scorecard [74] that has
recently evolved in a simplified one [75].
The RANO- and iRANO-BM response assessment cri-
teria undoubtedly provide a useful framework for a more
effective communication between the neuroradiologist,
the neuro-oncologist and clinicians utilizing immunother-
apy. Nonetheless, it is imperative for neuroradiologists to
be more comprehensively familiar with treatment re-
sponse criteria and treatment-induced changes of brain
lesions [62, 69–71]. Among these are radiation-induced
brain injuries that comprise a wide range of neuroradio-
logical findings resulting from fractionated or WBRT [76,
77], and include the development of pseudo-progression
of disease that typically occurs within the first 3 months
following therapy.
Furthermore, recent evidence suggest that ICI therapy
can increase: i) the rates of hemorrhage of melanoma
brain metastases treated with WBRT [78]; ii) the inci-
dence of radiation necrosis after treatment of brain me-
tastases with SRS [79]; iii) tumor pseudo-progressions
which typically occur within the first 3 months following
therapy and that is thought to represent a milder form
of radiation necrosis [61, 80, 81]. Immunotherapy alone
can also generate neuroradiological changes that may be
misplaced with tumor recurrence or progression [82].
Additionally, despite their prominent role in the RANO
and iRANO criteria gadolinium-enhanced T1-weighted im-
ages do not breakdown all possible changes occurring after
treatment of brain metastases. Thus, non-morphological
MR techniques may be useful to further differentiate re-
sidual/recurrent tumor from post-treatment changes. A
thoughtful synthesis using a combination of these tech-
niques can usually allow the neuroradiologist to correctly
discriminate tumor tissues from treatment-induced alter-
ations. Therefore, neuroradiologists need to have a thor-
ough knowledge of available conventional and advanced
techniques [62, 69–71, 83] to evaluate treatment response
and potential treatment-related complications. Also, PET-
based imaging, especially with aminoacid tracers, provides
information on tumor metabolism and is currently under
investigation to properly differentiate neoplastic tissues
from non-specific, treatment-related changes occurring
after surgery, radiotherapy, chemotherapy, and immuno-
therapy [84–87]. Recommendations on the clinical use of
PET in neuro-oncology have been recently reported [84].
Adverse events
In addition to these multiple challenges in response
evaluation of brain metastases, ICI therapy is well ac-
knowledged to lead to ir AEs in a proportion of patients.
Among these ir-hypophysitis (HP) can occur during
treatment with a higher frequency in patients undergo-
ing CTLA-4 blockade [88]. Notably, the incidence of ir-
HP ranges from 0.5 to 18%, depending on the dose of
anti-CTLA-4 therapy utilized, and from its combination
with PD-1 blocking agents [89]; conversely, ir-HP is in-
frequent in patients treated with single agent PD-1/PD-
L1 blockade. Despite HP must be differentiated from
metastatic disease to the hypophysis (accounting for
0.87% of patients with intracranial metastases), its diag-
nosis is mainly “presumptive” as no surgery is usually
performed. Thus, the diagnosis of HP is mostly based on
the association of clinical signs and hormonal deficits
and abnormalities, hyponatremia, and/or pituitary im-
aging abnormalities suggestive for HP. Furthermore, the
pituitary gland may appear normal at first MRI, though
it does not necessarily rule out HP [90].
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More rare and potentially fatal ICI-mediated neurologic
complications, including limbic encephalitis, aseptic men-
ingitis, Guillain-Barré syndrome, transverse myelitis, my-
asthenia inflammatory myopathy, and orbital myositis,
have been reported [91–93]. These uncommon toxicities
and their swift diagnosis and optimal clinical manage-
ment, undoubtedly necessitate a multidisciplinary team
approach that must include the neuroradiologist.
Conclusion
The forthcoming results of ICI-based therapeutic combi-
nation(s) in patients with brain disease may soon lead to
significant changes in their comprehensive management,
thus revisiting the role of surgery and radiotherapy in
CNS metastases. Nevertheless, the efficacy of ICI therapy
on brain metastases from tumors where ICI therapy is
already the standard of care requires a thoughtful, case-
by-case, evaluation on the optimal therapeutic approach
to be pursued. In selected cases, ICI therapy alone could
indeed represent the optimal therapeutic choice. In this
daily practice scenario, as well as when patients with
CNS metastases are enrolled in clinical trials, a multidis-
ciplinary interaction is mandatory for their optimal
management and must undoubtedly include the neuro-
radiologist to support treating physicians in evaluating
clinical response and neurological side effects.
Upcoming insights from pre-clinical and clinical stud-
ies will also allow designing new therapeutic strategies
to overcome the limitations deriving from the highly im-
munosuppressive TME of brain metastases.
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